Clinical features and mortality outcomes of patients with MASLD only compared to those with MAFLD and MASLD.

IF 5.9 2区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Hepatology International Pub Date : 2024-08-28 DOI:10.1007/s12072-024-10721-2

Mingqian Jiang, Ziyan Pan, Jacob George, Mohammed Eslam

{"title":"Clinical features and mortality outcomes of patients with MASLD only compared to those with MAFLD and MASLD.","authors":"Mingqian Jiang, Ziyan Pan, Jacob George, Mohammed Eslam","doi":"10.1007/s12072-024-10721-2","DOIUrl":null,"url":null,"abstract":"Background and aims: The applicability of the proposed metabolic dysfunction-associated steatotic liver disease (MASLD) definition has not been validated. We aimed to characterize the profiles and long-term survival of people meeting the criteria for MASLD, but not that of metabolic dysfunction-associated fatty liver disease (MAFLD), i.e. MASLD only.Methods: Using data from the Third National Health and Nutrition Examination Survey (NHANES III) 1988-1994, 7791 adult participants were included and categorized into four distinct groups: no SLD, non-MAFLD MASLD, MASLD-MAFLD, and cryptogenic SLD (steatosis without metabolic dysfunction).Results: Participants in the MASLD-only group were younger and had better metabolic profiles and fibrosis degree compared to those with MASLD-MAFLD and those with no SLD. Their profiles were comparable to those with cryptogenic SLD. Similarly, the MASLD-only group tend to have lower cumulative incidence of all-cause and cardiovascular mortality. Clustering analysis showed that MASLD only clusters differently from individuals with MASLD-MAFLD.Conclusions: MASLD only is a distinct clinical group with substantial heterogeneity compared to those captured using the MAFLD criteria.","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":null,"pages":null},"PeriodicalIF":5.9000,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatology International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12072-024-10721-2","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background and aims: The applicability of the proposed metabolic dysfunction-associated steatotic liver disease (MASLD) definition has not been validated. We aimed to characterize the profiles and long-term survival of people meeting the criteria for MASLD, but not that of metabolic dysfunction-associated fatty liver disease (MAFLD), i.e. MASLD only.

Methods: Using data from the Third National Health and Nutrition Examination Survey (NHANES III) 1988-1994, 7791 adult participants were included and categorized into four distinct groups: no SLD, non-MAFLD MASLD, MASLD-MAFLD, and cryptogenic SLD (steatosis without metabolic dysfunction).

Results: Participants in the MASLD-only group were younger and had better metabolic profiles and fibrosis degree compared to those with MASLD-MAFLD and those with no SLD. Their profiles were comparable to those with cryptogenic SLD. Similarly, the MASLD-only group tend to have lower cumulative incidence of all-cause and cardiovascular mortality. Clustering analysis showed that MASLD only clusters differently from individuals with MASLD-MAFLD.

Conclusions: MASLD only is a distinct clinical group with substantial heterogeneity compared to those captured using the MAFLD criteria.

Abstract Image

查看原文本刊更多论文

仅患有 MASLD 的患者与患有 MAFLD 和 MASLD 的患者的临床特征和死亡率比较。

背景和目的：代谢功能障碍相关性脂肪性肝病（MASLD）定义的适用性尚未得到验证。我们旨在描述符合代谢功能障碍相关性脂肪性肝病（MASLD）标准而不符合代谢功能障碍相关性脂肪性肝病（MAFLD）标准（即仅符合代谢功能障碍相关性脂肪性肝病）的人群的特征和长期生存情况：方法：利用 1988-1994 年第三次全国健康与营养调查（NHANES III）的数据，纳入 7791 名成年参与者，并将其分为四组：无 SLD、非 MAFLD MASLD、MASLD-MAFLD 和隐源性 SLD（无代谢功能障碍的脂肪肝）：结果：与MASLD-MAFLD和无SLD患者相比，纯MASLD组患者更年轻，代谢状况和纤维化程度更好。他们的情况与隐源性 SLD 患者相当。同样，仅MASLD组的全因死亡率和心血管死亡率的累积发生率也较低。聚类分析显示，仅MASLD患者的聚类与MASLD-MAFLD患者不同：结论：与采用MAFLD标准的患者相比，仅MASLD患者是一个独特的临床群体，具有很大的异质性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hepatology International 医学-胃肠肝病学

CiteScore

10.90

自引率

3.00%

发文量

167

审稿时长

6-12 weeks

期刊介绍： Hepatology International is the official journal of the Asian Pacific Association for the Study of the Liver (APASL). This is a peer-reviewed journal featuring articles written by clinicians, clinical researchers and basic scientists is dedicated to research and patient care issues in hepatology. This journal will focus mainly on new and emerging technologies, cutting-edge science and advances in liver and biliary disorders. Types of articles published: -Original Research Articles related to clinical care and basic research -Review Articles -Consensus guidelines for diagnosis and treatment -Clinical cases, images -Selected Author Summaries -Video Submissions